Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000728434 | SCV000856012 | uncertain significance | not provided | 2017-08-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001862146 | SCV002309068 | uncertain significance | Muscle AMP deaminase deficiency | 2022-06-04 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 239 of the AMPD1 protein (p.Tyr239Cys). This variant is present in population databases (rs376201207, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with AMPD1-related conditions. ClinVar contains an entry for this variant (Variation ID: 593406). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004026945 | SCV004894966 | uncertain significance | Inborn genetic diseases | 2023-10-02 | criteria provided, single submitter | clinical testing | The c.716A>G (p.Y239C) alteration is located in exon 6 (coding exon 6) of the AMPD1 gene. This alteration results from a A to G substitution at nucleotide position 716, causing the tyrosine (Y) at amino acid position 239 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |